| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
EXEL Stock Overview
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
Exelixis Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.68 |
| 52 Week High | US$23.40 |
| 52 Week Low | US$15.50 |
| Beta | 0.65 |
| 1 Month Change | -12.45% |
| 3 Month Change | -27.31% |
| 1 Year Change | -27.21% |
| 3 Year Change | -7.95% |
| 5 Year Change | -39.01% |
| Change since IPO | 3.24% |
Recent News & Updates
Exelixis: Efforts Continue To Diversify The Pipeline
Summary Performance has been poor over the past five years even as executive compensation remains on the high end. Cabozantinib continues to show promising sales growth and retention of market share in key indications such as renal cell carcinoma. Partnering efforts focus on novel targets and innovative platform technologies, but are early stage in nature and unlikely to move the needle in the near term. Tissue Factor is a target of growing interest in the ADC space after FDA approval for Seagen's Tivdak and XB002 could potentially dose higher (and achieve better efficacy). EXEL is a Buy only for long-term investors, as near-term upside could be limited. Key risks include ongoing battle over IP from generic competitors and potential to overpay for acquiring a late-to-commercial stage asset. Shares of midcap biotechnology company Exelixis (EXEL) have risen by just 44% since I called the stock a compelling buy in 2016. Performance is a dismal 31% loss since my 2017 update, and so far in 2022 shares are flat. While it's true the stock has done little but fall or consolidate over the past few years, the underlying company has done anything but stay stagnant. An ongoing patent fight with Teva Pharmaceutical (TEVA) continues as the large pharmaceutical firm wants to market its generic drug before the 2032 expiry of U.S. Patent No. 11,298,349. Q2 update showed that Cabometyx revenues continued to grow at a healthy 22% rate, while multi-faceted pipeline continues to make progress with multiple studies ongoing. While it does not yield much fruit upfront, I am a fan of management's approach to partnering with innovative private biotech companies possessing complementary technology platforms (low upfront payments with majority of economics being success-based and backend-weighted in nature). Let's take a closer look to see how the story has progressed and whether this one is ready for the Core Biotech portfolio. Chart FinViz When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, we can see shares bounce around in the mid-teens to mid-twenties range over and again throughout the past few years. It would seem that the stock was a good buy each time it hit relative lows, and my initial take is that long-term investors would do well to accumulate dips in the second half of this year ahead of clinical momentum set to take place in the 2023-2025 timeframe (especially for the early-stage pipeline). Overview Founded in 1994 with headquarters in California (954 employees), Exelixis currently sports enterprise value of ~$3.7 billion and Q2 cash position of $2 billion providing them operational runway for quite some time (actually added $100M to its balance sheet during the quarter). Corporate Slides For those familiar with this midcap biotech company, the quarterly call is more than sufficient to get caught up to speed with the current snapshot. The simple version is that the cabozantinib franchise continues to see commercial growth both domestically in the US and internationally, while Exelixis works hard to bring forward next-generation TKI XL092 in the clinic for life cycle extension as the specter of generic competition looms for cabozantinib. Additionally, the company has a deep yet very early-stage pipeline consisting of next-generation antibody drug conjugates ((ADCS)) as well as inhibitors of multiple novel targets - the issue is that in the near term at least, such early data readouts (however promising) are not likely to shift Wall Street's attention from fears of generic competition (as early as 2026, more likely out to 2030). Corporate Slides Management highlights strong performance for Cabometyx in Q2 as leading TKI of choice for renal cell carcinoma ((RCC)), with sales growing 22% year over year (7th consecutive quarter of growth). Interestingly, they've seen a near doubling of new patient starts at the 40mg dose since CheckMate 9ER launch in January of last year. As for competition versus other TKIs (Inlyta, Sutent, Votrient, Lenvima), Cabo's market share has increased every quarter since Q1 2021 and was 37% for Q2 2022 (impressive considering how fiercely competitive this space is). In HCC, Cabo continues to be the most prescribed TKI in the 2nd line setting for patients treated with immunotherapy containing regimens in first line. In July, the company reported positive topline data for COSMIC-313 (evaluating cabozantinib in combination with nivolumab and ipilimumab in intermediate and poor risk renal cell carcinoma). The combo reduced risk of disease progression of death compared to ipi/nivo with hazard ratio of 0.73, p=0.01. Conversely, interim analysis of secondary endpoint of overall survival did not demonstrate significant benefit over comparator arm and so trial continues to the next analysis of OS. Another expansion effort is the phase 3 pivotal study of cabozantinib in combination with atezolizumab versus docetaxel in patients with metastatic NSCLC (non-small cell lung cancer) who have been previously treated with immune checkpoint inhibitor and platinum-containing chemotherapy. It was recommended that the study remain blinded at pre-planned interim analysis and so it will continue to final analysis of overall survival by the end of 2022. Similarly, for the CONTACT-03 study of cabozantinib in combination with atezolizumab in PD-1 experienced renal cell carcinoma, readout is expected on the progression-free survival endpoint in the next quarter or two. For CONTACT-02 (phase 3) study of cabozantinib in combination with atezolizumab in metastatic castration-resistant prostate cancer, enrollment should finish up by mid 2023. Moving on to the multi-faceted pipeline, next gen TKI XL092 (potentially improved tolerability versus cabozantinib due in part to shorter half-life) was the subject of a phase 3 study in non-MSI-high colorectal cancer initiated in June. The drug candidate is also being explored in combination with several checkpoint inhibitors and IO combinations with additional registrational studies planned. Corporate Slides Moving outside these efforts, XB002 is the company's first ADC (targets tissue factor, which readers may recall is also the target of Seagen's ADC Tivdak which was granted accelerated approval in cervical cancer). XB002's point of differentiation is its ability to target tissue factor without interfering with the coagulation pathway, and so far in dose escalation no bleeding events have been observed. The company expects to move into multi-cohort dose expansion phase later this year so perhaps we'll finally get some noteworthy data from this asset in the 2023 to 2024 timeframe. Corporate Slides Moving on to a lesser-known candidate, the company's oral CDK7 inhibitor XL102 is the subject of a phase 1 study and expected to move into monotherapy and combo expansion cohorts after recommended phase 2 dose is determined. On the whole, we are reminded that the pipeline consists of both internal and collaboration-derived candidates with over 10 programs in progress and potential to progress up to 5 compounds into preclinical development this year with more to come in 2023. While such compounds are unlikely to assuage Wall Street's concerns about dependence on Cabo revenues given how early stage these assets are, they do look quite novel (not "me too" drugs). This includes XB010 (novel ADC targeting 5T4) moving into preclinical development and their first bispecific XBO014 targeting PD-L1 and CD47 moving into preclinical as well. 2 recent deals are synonymous with management's partnering approach, one that infuriates (or at least gets no respect from) Wall Street given that programs arising from collaboration efforts are not likely to generate needle-moving data for years to come. I, on the other hand, am a fan of such deals as they are backend-weighted with low upfront commitment of cash resources. One of these recent deals was the agreement with BioInvent to identify novel targets and antibodies with their platform (uses primary human tumor material as a starting point for parallel tumor-specific target identification and antibody discovery). Under the agreement, Exelixis can select 3 targets to license upon identification of development candidates against those targets. In a similar manner, the Ryvu deal allows for access to their proprietary STING agonists which Exelixis intends to utilize and construct novel immunostimulatory ADCs (I note that multiple next generation ADC companies like Mersana Therapeutics and Sutro Biopharma are also pursuing this path). In June this year Sutro (STRO) received $90M upfront from Astellas for its next-gen tech enabling immunostimulatory ADCs plus is eligible for over $400M in milestone payments for each candidate arising from these efforts (and of course royalties). Let's move on to recent news and how it's affected the investability of Exelixis in the near to medium term. Select Recent Developments On September 2, Exelixis filed a complaint in the United States District Court for the District of Delaware for patent infringement against Teva Pharmaceutical asserting infringement of U.S. Patent No. 11,298,349 arising from Teva's amendment of its Abbreviated New Drug Application. The short version is that Teva filed an ANDA to the FDA for a generic version of Cabometyx tablets (covering 20mg, 40mg and 60 mg doses) and Exelixis received notice on July 29th about the large company's intention to market a generic version of Cabo before the expiration of U.S. Patent No. 11,298,349. Exelixis wants the patent to stand with its expiration date in 2032. It will be interesting to see how court proceedings and associated drama pan out in coming years (hard to have an edge in determining who has the edge). The weak chart for Exelixis' stock suggests some credence of these generic fears is being given by Wall Street analysts. This follows Exelixis' July lawsuit against MSN Pharmaceuticals similarly asserting infringement of U.S. Patent No. 11,298,349 expiring in 2032 (contends no generic approval should become valid until then). When in doubt, I prefer to use worst case scenario as my baseline investment case so let's assume composition of matter patent holds up but polymorph patent does not (thus allowing for protection only until 2026 and thus we could see a generic launch in 4 years). Again, Exelixis still has multiple avenues of dispute to pursue and no expert can say with certainty how this will play out. Moving on to September 10th, Exelixis announced results from the ongoing phase 1b study evaluating XL092 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The highlight was activity in heavily pretreated RCC patients who received prior treatment with immunotherapy and/or VEGF-targeting TKIs, including 70% of patients who received cabozantinib as a prior treatment. Maximum tolerated dose was 120mg and go-forward dose was determined to be 100mg for both single agent and combination with atezolizumab. Tumor reduction was observed in 71% of patients on single agent XL092 and 56% of combo patients, while ORR was 10% for single agent and 4% for combo. Other Information For the second quarter of 2022, the company reported cash and equivalents of $2 billion (up $100M from prior quarter). Total revenues were $419M, while net product revenues rose from $284M to $347M. Research and development expenses rose by about 30% to $200M, while SG&A similarly rose to $123M. Accumulated deficit is just $216M, showing that leadership in general has done a good job of resource allocation and management as Cabo revenues help fund pipeline development. From the conference call, I liked management commentary on XB002 considering recent approval of Seagen's Tivdak and growing interest in Tissue Factor as a target. 20% of patients in Tivdak pivotal trial had ocular adverse events leading to dose reduction and 5% of patients discontinued treatment. Management states that for XB002, there are a number of differentiating factors they consider compelling. The antibody is not the same and binds to a different epitope on tissue factor. It was very carefully selected so that the epitope does not interfere with Factor VII binding and thus does not interfere with coagulation at all. Second is the payload linker, using a ZymeLink payload from Zymeworks (modified oral statin, not standard MMAE and has been heavily modified with different linker). Preclinically on dosing, they see very low levels of free circulating payload while still maintaining good levels of intact ADC. The promise of 002 could be its ability to dose higher than what Tivdak could do and thus have increased efficacy. As for institutional investors of note, I see very few specialist healthcare funds here and more in the way of generalists such as Vanguard Group with a 9.5% stake. As for insiders, history of sales and lack of buying does not inspire confidence. As for relevant leadership experience, EVP Product Development & Medical Affairs Vicki Goodman served prior as VP Clinical Research at Merck. CFO Christopher Senner served prior as VP Corporate Finance at Gilead Sciences. Moving on to executive compensation, cash portion of salaries seems excessive especially for CEO at over $1M (couple that with over 5M of option awards for what has been a meandering stock price for over the past 5 years and that does not sit right with me). Salaries for other executives seem reasonable on the whole, though again Former President of Product Development received over 7M of stock awards in 2021 which leaves a bad taste considering how poorly shareholders have done here over the past few years. Proxy Filing The important thing is to avoid companies where the management team is clearly in it for self-enrichment instead of creating value for shareholders, and looking at compensation is one of several indicators in that regard. As for IP, cabozantinib is covered by over 15 issued patents in the US including composition of matter (expires September 2024 but has been granted term extension to August 2026). Table below shows IP covering polymorphic forms of cabozantinib (expires 2030), methods of treatment (out to 2037) and other assorted patents that hopefully help the company extend the life of this franchise farther out. Again, the key risk here is that by 2026 a generic alternative comes to market via MSN, Teva or other competitors. 10-K filing
Exelixis, Teva fight over Cabometyx generic again
Cancer-focused biotech Exelixis, Inc. (NASDAQ:EXEL) has filed another court case against Israeli drugmaker Teva Pharmaceutical Industries (TEVA) on allegations of patent infringement related to a generic version of the company’s kidney cancer therapy Cabometyx. The lawsuit filed in the District Court in Delaware asserts infringement of U.S. Patent No. 11,298,349 due to an amendment in TEVA’s marketing application for a generic version of Cabometyx, EXEL said in a regulatory filing. With the amendment for the Abbreviated New Drug Application, TEVA seeks to market its generic drug before the 2032 expiry of the patent. Considered a standard of care for renal cell carcinoma, Cabometyx added more than $1B in net product revenue for EXEL in 2021. Two companies are engaged in a separate patent infringement case involving certain other Cabometyx patents, the latest of which expires in Jul. 2033.
Shareholder Returns
| EXEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.7% | 0.4% | -2.5% |
| 1Y | -27.2% | -25.6% | -23.2% |
Return vs Industry: EXEL underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: EXEL underperformed the US Market which returned -23.2% over the past year.
Price Volatility
| EXEL volatility | |
|---|---|
| EXEL Average Weekly Movement | 4.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: EXEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: EXEL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 954 | Mike Morrissey | https://www.exelixis.com |
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis Fundamentals Summary
| EXEL fundamental statistics | |
|---|---|
| Market Cap | US$5.05b |
| Earnings (TTM) | US$272.62m |
| Revenue (TTM) | US$1.55b |
18.5x
P/E Ratio3.2x
P/S RatioIs EXEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXEL income statement (TTM) | |
|---|---|
| Revenue | US$1.55b |
| Cost of Revenue | US$51.48m |
| Gross Profit | US$1.50b |
| Other Expenses | US$1.23b |
| Earnings | US$272.62m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.85 |
| Gross Margin | 96.69% |
| Net Profit Margin | 17.53% |
| Debt/Equity Ratio | 0% |
How did EXEL perform over the long term?
See historical performance and comparisonValuation
Is EXEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EXEL?
Other financial metrics that can be useful for relative valuation.
| What is EXEL's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$5.05b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.4x |
| Enterprise Value/EBITDA | 10.5x |
| PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does EXEL's PE Ratio compare to its peers?
| EXEL PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.7x | ||
HALO Halozyme Therapeutics | 14.9x | 24.6% | US$5.4b |
UTHR United Therapeutics | 15.1x | 17.1% | US$9.5b |
INCY Incyte | 15.7x | 28.6% | US$14.8b |
XNCR Xencor | 69x | 18.8% | US$1.6b |
EXEL Exelixis | 18.5x | 23.0% | US$5.0b |
Price-To-Earnings vs Peers: EXEL is good value based on its Price-To-Earnings Ratio (18.5x) compared to the peer average (28.7x).
Price to Earnings Ratio vs Industry
How does EXEL's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: EXEL is expensive based on its Price-To-Earnings Ratio (18.5x) compared to the US Biotechs industry average (14.9x)
Price to Earnings Ratio vs Fair Ratio
What is EXEL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.5x |
| Fair PE Ratio | 26.2x |
Price-To-Earnings vs Fair Ratio: EXEL is good value based on its Price-To-Earnings Ratio (18.5x) compared to the estimated Fair Price-To-Earnings Ratio (26.2x).
Share Price vs Fair Value
What is the Fair Price of EXEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EXEL ($15.68) is trading below our estimate of fair value ($82.49)
Significantly Below Fair Value: EXEL is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Future Growth
How is Exelixis forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
23.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXEL's forecast earnings growth (23% per year) is above the savings rate (1.9%).
Earnings vs Market: EXEL's earnings (23% per year) are forecast to grow faster than the US market (14.8% per year).
High Growth Earnings: EXEL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EXEL's revenue (10.9% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: EXEL's revenue (10.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXEL's Return on Equity is forecast to be low in 3 years time (17.3%).
Discover growth companies
Past Performance
How has Exelixis performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-7.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EXEL has high quality earnings.
Growing Profit Margin: EXEL's current net profit margins (17.5%) are higher than last year (8.1%).
Past Earnings Growth Analysis
Earnings Trend: EXEL's earnings have declined by 7.5% per year over the past 5 years.
Accelerating Growth: EXEL's earnings growth over the past year (189.9%) exceeds its 5-year average (-7.5% per year).
Earnings vs Industry: EXEL earnings growth over the past year (189.9%) exceeded the Biotechs industry 29.2%.
Return on Equity
High ROE: EXEL's Return on Equity (11.4%) is considered low.
Discover strong past performing companies
Financial Health
How is Exelixis's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: EXEL's short term assets ($1.9B) exceed its short term liabilities ($304.5M).
Long Term Liabilities: EXEL's short term assets ($1.9B) exceed its long term liabilities ($185.6M).
Debt to Equity History and Analysis
Debt Level: EXEL is debt free.
Reducing Debt: EXEL had no debt 5 years ago.
Debt Coverage: EXEL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: EXEL has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is Exelixis's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
| Exelixis Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (Exelixis) | n/a |
| Market Bottom 25% (US) | 1.7% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Biotechs) | 2.8% |
| Analyst forecast in 3 Years (Exelixis) | 0% |
Notable Dividend: Unable to evaluate EXEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EXEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EXEL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EXEL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EXEL has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
7.3yrs
Average management tenure
CEO
Mike Morrissey (61 yo)
12.25yrs
Tenure
US$7,530,431
Compensation
Dr. Michael M. Morrissey, Ph D., also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24...
CEO Compensation Analysis
| Mike Morrissey's Compensation vs Exelixis Earnings |
|---|
| Date | Total Comp. | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | US$273m |
| Mar 31 2022 | n/a | n/a | US$298m |
| Dec 31 2021 | US$8m | US$1m | US$231m |
| Sep 30 2021 | n/a | n/a | US$164m |
| Jun 30 2021 | n/a | n/a | US$94m |
| Mar 31 2021 | n/a | n/a | US$65m |
| Dec 31 2020 | n/a | n/a | US$112m |
| Sep 30 2020 | n/a | n/a | US$152m |
| Jun 30 2020 | n/a | n/a | US$282m |
| Mar 31 2020 | n/a | n/a | US$294m |
| Dec 31 2019 | n/a | n/a | US$321m |
| Sep 30 2019 | n/a | n/a | US$612m |
| Jun 30 2019 | n/a | n/a | US$642m |
| Mar 31 2019 | n/a | n/a | US$650m |
| Dec 31 2018 | n/a | n/a | US$690m |
| Sep 30 2018 | n/a | n/a | US$368m |
| Jun 30 2018 | n/a | n/a | US$323m |
| Mar 31 2018 | n/a | n/a | US$253m |
| Dec 31 2017 | n/a | n/a | US$154m |
| Sep 30 2017 | n/a | n/a | US$150m |
| Jun 30 2017 | n/a | n/a | US$58m |
| Mar 31 2017 | n/a | n/a | US$6m |
| Dec 31 2016 | n/a | n/a | -US$70m |
| Sep 30 2016 | n/a | n/a | -US$147m |
| Jun 30 2016 | n/a | n/a | -US$181m |
| Mar 31 2016 | n/a | n/a | -US$186m |
Compensation vs Market: Mike's total compensation ($USD7.53M) is about average for companies of similar size in the US market ($USD8.66M).
Compensation vs Earnings: Mike's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: EXEL's management team is seasoned and experienced (7.3 years average tenure).
Board Members
Experienced Board: EXEL's board of directors are seasoned and experienced ( 18 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Date | Value | Name | Entity | Role | Shares | Max Price |
|---|---|---|---|---|---|---|
| 27 May 22 | SellUS$342,567 | Patrick Haley | Individual | 18,812 | US$18.21 | |
| 25 Feb 22 | SellUS$610,078 | Patrick Haley | Individual | 31,238 | US$19.53 | |
| 22 Feb 22 | SellUS$1,653,113 | Stelios Papadopoulos | Individual | 84,515 | US$19.56 | |
| 24 Nov 21 | SellUS$297,321 | Patrick Haley | Individual | 17,236 | US$17.25 |
Ownership Breakdown
| Owner Type | Number of Shares | Ownership Percentage |
|---|---|---|
| State or Government | 141,012 | 0.04% |
| Individual Insiders | 5,082,655 | 1.6% |
| Hedge Funds | 17,783,937 | 5.5% |
| General Public | 33,949,705 | 10.5% |
| Institutions | 264,874,475 | 82.3% |
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
Top Shareholders
| Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
|---|---|---|---|---|---|---|
| 33,556,731 | $526.2m | 2.04% | 0.01% | |||
| 31,064,733 | $487.1m | 2.63% | 0.01% | |||
| 17,783,937 | $278.9m | 5.47% | 0.35% | |||
| 17,393,828 | $272.7m | 1.15% | 0.03% | |||
| 13,425,015 | $210.5m | -14.89% | 0.03% | |||
| 12,596,380 | $197.5m | 10.72% | 0.01% | |||
| 11,317,908 | $177.5m | 1.08% | 0.03% | |||
| 10,174,273 | $159.5m | -3.29% | 1.23% | |||
| 7,720,300 | $121.1m | -14.07% | 73.55% | |||
| 4,262,588 | $66.8m | -0.26% | 0.01% | |||
| 4,049,209 | $63.5m | -0.12% | 1.2% | |||
| 3,779,563 | $59.3m | 1.3% | 0.02% | |||
| 3,585,906 | $56.2m | 15.22% | 0.01% | |||
| 3,513,250 | $55.1m | 441.61% | 0.02% | |||
| 3,262,192 | $51.2m | -8.43% | 0.06% | |||
| 3,053,793 | $47.9m | 3.42% | 0.01% | |||
| 3,032,964 | $47.6m | 0% | 0.01% | |||
| 2,829,413 | $44.4m | 24.12% | 0.02% | |||
| 2,689,548 | $42.2m | -1.61% | 0.06% | |||
| 2,678,500 | $42.0m | -1.49% | 0.47% | |||
| 2,647,885 | $41.5m | -1.28% | 0.3% | |||
| 2,480,977 | $38.9m | 379.28% | 0.06% | |||
| 2,479,977 | $38.9m | 45.35% | 0.03% | |||
| 2,443,152 | $38.3m | -1.18% | 0.01% | |||
| 2,319,559 | $36.4m | -3.32% | 0.29% |
Company Information
Exelixis, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Exelixis, Inc.
- Ticker: EXEL
- Exchange: NasdaqGS
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.046b
- Shares outstanding: 321.83m
- Website: https://www.exelixis.com
Number of Employees
Location
- Exelixis, Inc.
- 1851 Harbor Bay Parkway
- Alameda
- California
- 94502
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EXEL | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Apr 2000 |
| EX9 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 2000 |
| EX9 | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Apr 2000 |
| 0IJO | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Apr 2000 |
| E2XE34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 2 REPR 1 COM | BR | BRL | Jan 2022 |
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/02 00:00 |
| End of Day Share Price | 2022/09/30 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.